Ethics & Informed Consent: Randomised Controlled Trial (RCT) (Singapore)
A detailed academic review of the ethical submission protocol, informed consent prerequisites, and reporting standards for conducting a Randomised Controlled Trial (RCT) within the regulatory framework of Singapore.
1. Ethical Principles & Legislative Framework
In research involving human participants, securing ethical clearance is a critical first step. For a Randomised Controlled Trial (RCT) being conducted in Singapore, study designs must align with the primary regulatory legislation: Human Biomedical Research Act (HBRA). This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.
National Ethics Board Clearance Pathway
In Singapore, human biomedical research is governed by the Human Biomedical Research Act (HBRA), which defines strict penalties for non-compliance. Ethical clearance must be obtained from an institutional IRB or an appointed Institutional Ethics Committee. Personal data protection must adhere to the Personal Data Protection Act (PDPA), which governs the collection, use, and disclosure of personal data for research.
Administrative review and formal approval are managed by a local or regional Institutional Review Board (IRB). Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.
2. Study Design Elements & Reporting Integrity
For a Randomised Controlled Trial (RCT), the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.
Study Classification: High Risk (Interventional)
This interventional trial requires strict protocol adherence, allocation concealment, robust adverse event monitoring, and emergency unblinding guidelines.
To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: CONSORT statement.
Special Directive: Interventional Study Protocols
Because this study design is classified as interventional, the Institutional Review Board (IRB) requires pre-registration of the trial on a public clinical registry (e.g. ClinicalTrials.gov or a regional WHO-compliant database) before patient enrolment begins. A detailed adverse event reporting protocol must also be submitted.
3. Informed Consent & Information Sheet Guidelines
A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:
Design-Specific Consent Focus Areas
Disclosure of placebo controls, monitoring of adverse events, side effect profiles, and random assignment protocols.
- Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
- Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
- Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under Personal Data Protection Act (PDPA).
- Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
- Ethics Board Contact Information: Provide the contact details of the reviewing Institutional Review Board (IRB) so participants can reach out if they have questions or concerns.
Research Ethics, Clinical Trials & Institutional Governance
To run a high-quality Randomised Controlled Trial (RCT) in Singapore, the protocol must strictly observe the Declaration of Helsinki ethical principles for clinical trials. Under active regulations, investigators must explicitly justify if any temporary deception in psychological research is planned for patients. The communication process must uphold the core ethical principles of informed consent, detailing voluntary withdrawal rights. Pre-requisites for starting the trial include a formal clinical trial registration and a signed clinical trial agreement contract. The research team must document all safety parameters to obtain complete research ethics approval from the Institutional Review Board (IRB). Ethical oversight committees in Singapore audit the study's consent registry periodically to verify compliance with national legal statutes.
4. Regulatory Checklist Table
To streamline your ethical review submission, use the structured alignment checklist below:
| Requirement | Institutional Review Board (IRB) Standard | CONSORT statement Standard |
|---|---|---|
| Consent Form | Signed and dated prior to study activity. Focus: Disclosure of placebo controls. | Fully documented recruitment and consent paths. |
| Risk Management | Comprehensive risk mitigation plan. Mandates establishing an independent Data Safety Monitoring Board (DSMB) and registering the trial on a public registry (e.g., ClinicalTrials.gov). | Adverse events reporting strategy. |
| Data Retention | Compliance with local data protection rules (Personal Data Protection Act (PDPA)). | Provision of open-data options where possible. |
5. Academic & Research Infrastructure Matrix (Singapore)
The following authenticated registry lists top scientific organizations, clinical laboratories, and research hospitals in Singapore mapped via the Research Organization Registry (ROR) standards-compliance framework.
| Organization Name | Sector Type | Registry Identification |
|---|---|---|
| Singapore Telecommunications Limited | company | ROR ID |
| Medtronic (Singapore) | company | ROR ID |
| MediaTek (Singapore) | company | ROR IDWikidata/Wiki |
| Sivantos (Singapore) | company | ROR IDWikidata/Wiki |
| Siemens (Singapore) | company | ROR IDWikidata/Wiki |
| Danaher (Singapore) | company | ROR IDWikidata/Wiki |
| Abbott (Singapore) | company | ROR IDWikidata/Wiki |
| AstraZeneca (Singapore) | company | ROR IDWikidata/Wiki |
| Merck (Singapore) | company | ROR IDWikidata/Wiki |
| Takeda (Singapore) | company | ROR IDWikidata/Wiki |
| Advantest (Singapore) | company | ROR IDWikidata/Wiki |
| Safran (Singapore) | company | ROR IDWikidata/Wiki |
| GlobalFoundries (Singapore) | company | ROR IDWikidata/Wiki |
| TDK (Singapore) | company | ROR IDWikidata/Wiki |
| Hillrom (Singapore) | company | ROR IDWikidata/Wiki |
6. Frequently Asked Questions
How long does the review process normally take?
Review timelines depend on the volume of applications and whether your proposal qualifies for expedited review. On average, a standard review by an ethics board in Singapore takes between 4 to 8 weeks.
Can we use digital signatures for informed consent?
Yes, digital consent forms are increasingly accepted, provided the platform used is secure, authenticates the identity of the signer, and complies with local regulations such as the eIDAS or ESIGN Act, depending on country-specific rules.
Regulatory Context
Verified Funding Bodies
Funder registries and DOI configurations verified for compliance in Singapore via Crossref.
- Singapore Police ForceID: 501100001472 | Location: Singapore
- Economic Development Board - SingaporeID: 501100001446 | Location: Singapore
- Health Promotion Board - SingaporeID: 501100001448 | Location: Singapore
- Public Utilities Board - SingaporeID: 501100001467 | Location: Singapore
- Singapore's National Water AgencyID: 501100018705 | Location: Singapore
- Singapore Institute of TechnologyID: 100031556 | Location: Singapore
- National Library Board - SingaporeID: 501100001465 | Location: Singapore
- Ministry of Health -SingaporeID: 501100001350 | Location: Singapore
- Precision Health Research, SingaporeID: 501100022247 | Location: Singapore
- Singapore-ETH CentreID: 501100015833 | Location: Singapore
Pre-Submission Warning
Do not recruit participants or initiate study procedures before receiving official written approval from your reviewing board. Ethical approvals cannot be granted retrospectively under Human Biomedical Research Act (HBRA).







